Page last updated: 2024-08-24

capecitabine and sirolimus

capecitabine has been researched along with sirolimus in 18 studies

Research

Studies (18)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (11.11)	29.6817
2010's	15 (83.33)	24.3611
2020's	1 (5.56)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Collingridge, D	1
Sherman, WH	1
Mehta, SP	1
Eriksson, B	1
Cannistra, SA; Disis, ML; Verweij, J	1
Albanell, J; Berk, L; Capri, G; Cerny, T; Corradino, I; Cresta, S; Gianni, L; Haluska, F; Hess, D; Locatelli, A; Marsoni, S; Maur, M; Perotti, A; Rivera, VM; Rojo, F; Sessa, C; Viganò, L	1
Ahn, HK; Baek, KK; Han, B; Kang, WK; Kim, KM; Lee, DJ; Lee, HY; Lee, J; Lee, SJ; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS	1
Beijnen, JH; Deenen, MJ; Klümpen, HJ; Richel, DJ; Schellens, JH; Sparidans, RW; Weterman, MJ; Wilmink, JW	1
Klümpen, HJ; Kordes, S; Richel, DJ; Stevens, AJ; Weterman, MJ; Wilmink, JW	1
Kaklamani, V; Raffin, M; Reddy, S	1
Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C	1
Do, IG; Jung, SH; Kang, WK; Kim, KM; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS	1
Arrowood, CC; Bendell, JC; Brady, JC; Broderick, S; Cushman, SM; Dellinger, A; Hsu, SD; Hurwitz, HI; Kozloff, MF; Meadows, J; Meadows, KL; Morse, MA; Murphy, J; Nixon, AB; Pang, H; Rangwala, F; Starodub, AN; Starr, A; Strickler, JH; Tourt-Uhlig, S; Uronis, HE; Wallace, J; Zafar, SY	1
Klümpen, HJ; Kordes, S; Richel, DJ; Schellens, JH; Weterman, MJ; Wilmink, JW	1
Que, SKT; Schmults, CD; Zwald, FO	1
Cao, L; Chen, T; Duan, J; Kong, D; Lu, J; Ren, J; Shen, Z; Sun, Q; Wang, H; Wang, Z; Yang, R; Yoshida, S; Zheng, H	1

Reviews

4 review(s) available for capecitabine and sirolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Palliative chemotherapy for pancreatic malignancies. The Surgical clinics of North America, 2010, Volume: 90, Issue:2 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus	2010
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Current opinion in oncology, 2010, Volume: 22, Issue:4 Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome	2010
Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors. Journal of the American Academy of Dermatology, 2018, Volume: 78, Issue:2 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Capecitabine; Carcinoma, Squamous Cell; Chemoprevention; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lymph Nodes; Lymphatic Metastasis; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Multiple Primary; Organ Transplantation; Programmed Cell Death 1 Receptor; Radiotherapy, Adjuvant; Sirolimus; Skin Neoplasms	2018

Trials

8 trial(s) available for capecitabine and sirolimus

Article	Year
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30 Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Cell Cycle Proteins; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Europe; Female; Fluorouracil; Granulation Tissue; Humans; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; Skin; Thymidine Phosphorylase; Thymidylate Synthase; TOR Serine-Threonine Kinases; Treatment Outcome	2010
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus; Stomach Neoplasms; Treatment Outcome	2011
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Investigational new drugs, 2012, Volume: 30, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Everolimus; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Sirolimus; TOR Serine-Threonine Kinases; Young Adult	2012
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Investigational new drugs, 2013, Volume: 31, Issue:1 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sirolimus; Treatment Outcome	2013
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8 Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate	2013
Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. Investigational new drugs, 2013, Volume: 31, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Sirolimus; Stomach Neoplasms; Young Adult	2013
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Investigational new drugs, 2014, Volume: 32, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Everolimus; Female; Fluorouracil; Humans; Immunosuppressive Agents; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neuropilin-1; Neuropilin-2; Organoplatinum Compounds; Oxaliplatin; RNA, Messenger; Sirolimus; Vascular Endothelial Growth Factor A	2014
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases	2015

Other Studies

6 other study(ies) available for capecitabine and sirolimus

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
San Antonio Breast Cancer Symposium. The Lancet. Oncology, 2008, Volume: 9, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles	2008
Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer. JOP : Journal of the pancreas, 2009, Jul-06, Volume: 10, Issue:4 Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Sirolimus; Treatment Outcome	2009
Phase I studies of drug combinations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-20, Volume: 28, Issue:30 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Evidence-Based Medicine; Fluorouracil; Humans; Intracellular Signaling Peptides and Proteins; Maximum Tolerated Dose; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome	2010
Targeting angiogenesis in metastatic breast cancer. The oncologist, 2012, Volume: 17, Issue:8 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
Metronomic capecitabine with rapamycin exerts an immunosuppressive effect by inducing ferroptosis of CD4 International immunopharmacology, 2023, Volume: 124, Issue:Pt A Topics: Animals; Capecitabine; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; Ferroptosis; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Rats; Sirolimus; T-Lymphocytes	2023